Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.

@article{Corrie2014AdjuvantBI,
  title={Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study.},
  author={Pippa G. Corrie and Andrea R. Marshall and Janet. A. Dunn and Mark R. Middleton and Paul Nathan and Martin Eric Gore and Neville G Davidson and Steve Nicholson and Charles G. Kelly and Maria Marples and Sarah J. Danson and Ernest Marshall and Stephen J Houston and R E Board and Ashita Marie Waterston and Jenny P Nobes and Mark Harries and Satish Kumar and Gemma Young and Paul C. Lorigan},
  journal={The Lancet. Oncology},
  year={2014},
  volume={15 6},
  pages={620-30}
}
BACKGROUND Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of recurrence. We report results from the preplanned interim analysis. METHODS We did a multicentre, open-label, randomised controlled phase 3 trial at 48 centres in the UK between July 18, 2007, and March 29, 2012. Patients aged 16 years or older with… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

BRAF inhibition increases tumour inÞ

  • C Liu, W Peng, C Xu
  • c-cancer-immunotherap.html (accessed Feb
  • 2014

The investigational MAGE - A 3 antigen - speci fi c cancer immunotherapeutic does not meet fi rst co - primary endpoint in Phase III melanoma clinical trial

  • C Xu
  • 2013

Similar Papers

Loading similar papers…